DK1948689T3 - Højaktivitetsvækstfaktormutanter - Google Patents

Højaktivitetsvækstfaktormutanter

Info

Publication number
DK1948689T3
DK1948689T3 DK06818642.8T DK06818642T DK1948689T3 DK 1948689 T3 DK1948689 T3 DK 1948689T3 DK 06818642 T DK06818642 T DK 06818642T DK 1948689 T3 DK1948689 T3 DK 1948689T3
Authority
DK
Denmark
Prior art keywords
growth factor
high activity
factor mutants
activity growth
mutants
Prior art date
Application number
DK06818642.8T
Other languages
English (en)
Inventor
Jens Pohl
Frank Ploeger
Michael Kruse
Original Assignee
Bioph Biotech Entw Pharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37628151&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1948689(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioph Biotech Entw Pharm Gmbh filed Critical Bioph Biotech Entw Pharm Gmbh
Application granted granted Critical
Publication of DK1948689T3 publication Critical patent/DK1948689T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
DK06818642.8T 2005-11-18 2006-11-17 Højaktivitetsvækstfaktormutanter DK1948689T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05025261 2005-11-18
PCT/EP2006/011074 WO2007057212A1 (en) 2005-11-18 2006-11-17 High activity growth factor mutants

Publications (1)

Publication Number Publication Date
DK1948689T3 true DK1948689T3 (da) 2012-07-23

Family

ID=37628151

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06818642.8T DK1948689T3 (da) 2005-11-18 2006-11-17 Højaktivitetsvækstfaktormutanter

Country Status (13)

Country Link
US (3) US8188226B2 (da)
EP (1) EP1948689B1 (da)
JP (1) JP5654730B2 (da)
AT (1) ATE553123T1 (da)
AU (1) AU2006314713B2 (da)
CA (1) CA2627370C (da)
CY (1) CY1112877T1 (da)
DK (1) DK1948689T3 (da)
ES (1) ES2382464T3 (da)
PL (1) PL1948689T3 (da)
PT (1) PT1948689E (da)
SI (1) SI1948689T1 (da)
WO (1) WO2007057212A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4938628B2 (ja) * 2007-10-29 2012-05-23 Ｈｏｙａ株式会社 リン酸カルシウム系化合物、リン酸カルシウム系化合物／コラーゲン複合体及びリン酸カルシウム系細胞培養担体に付着又は吸着したエンドトキシンの抽出方法及び定量方法
JP2011522565A (ja) * 2008-06-09 2011-08-04 ワイス・エルエルシー 新規ｂｍｐ−１２関連タンパク質およびその製造方法
EP2602264A1 (en) * 2011-12-05 2013-06-12 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka mbH GDF-5 mutant for inducing cartilage formation
US9359417B2 (en) 2013-01-25 2016-06-07 Warsaw Orthopedic, Inc. Cell cultures and methods of human recombinant growth and differentiaton factor-5 (rhGDF-5)
US9051389B2 (en) 2013-01-25 2015-06-09 Warsaw Orthopedic, Inc. Expression conditions and methods of human recombinant growth and differentiation factor-5 (rhGDF-5)
US9169308B2 (en) 2013-01-25 2015-10-27 Warsaw Orthopedic, Inc. Methods and compositions of human recombinant growth and differentiation factor-5 (rhGDF-5) isolated from inclusion bodies
US8956829B2 (en) 2013-01-25 2015-02-17 Warsaw Orthopedic, Inc. Human recombinant growth and differentiaton factor-5 (rhGDF-5)
US8945872B2 (en) 2013-01-25 2015-02-03 Warsaw Orthopedic, Inc. Methods of purifying human recombinant growth and differentiation factor-5 (rhGDF-5) protein

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150328A (en) * 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
US5013649A (en) * 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
DE19525416A1 (de) 1995-07-12 1997-01-16 Bioph Biotech Entw Pharm Gmbh Verwendung von MP52 zur Behandlung und Prävention von Erkrankungen des Nervensystems
JP3645258B2 (ja) * 1993-01-12 2005-05-11 ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン 増殖分化因子−５
IL110589A0 (en) 1993-08-10 1994-11-11 Bioph Biotech Entw Pharm Gmbh Growth/differentiation factor of the TGF- beta family
DE69434651T2 (de) * 1993-12-07 2007-03-08 Genetics Institute, Inc., Cambridge Bmp-12, bmp-13 und diese enthaltende sehne-induzierende zusammensetzungen
WO1996014335A1 (en) 1994-11-07 1996-05-17 The Government Of The United States Of America, Asrepresented By The Secretary, Department Of Health And Human Services Cartilage-derived morphogenetic proteins
DE69636728T4 (de) 1995-04-19 2007-06-28 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Neues protein und verfahren zu dessen herstellung
JPH0931098A (ja) 1995-07-24 1997-02-04 Hoechst Japan Ltd 新規なタンパク質ｈｍｗヒトｍｐ５２
US5758328A (en) * 1996-02-22 1998-05-26 Giovannoli; Joseph Computerized quotation system and method
EP1074620A1 (en) 1999-08-06 2001-02-07 HyGene AG Monomeric protein of the TGF-beta family
JPH11335398A (ja) 1998-05-22 1999-12-07 Hoechst Marion Roussel Kk 新規な骨誘導活性を有する単量体蛋白質およびそれらからなる軟骨・骨疾患の予防および治療薬
CA2301693A1 (en) * 1997-09-19 1999-04-01 Klaus Unsicker Cytokines having neurotrophic activity
CA2344277A1 (en) * 1998-09-22 2000-03-30 University Of Maryland, Baltimore Cystine knot growth factor mutants
JP2000119192A (ja) * 1998-10-09 2000-04-25 Aventis Pharma Ltd 骨誘導因子アンタゴニスト活性を有する成熟型蛋白質
US5989863A (en) * 1998-10-14 1999-11-23 Incyte Pharmaceuticals, Inc. Human ankyrin family protein
AU2001290934A1 (en) 2000-09-12 2002-03-26 Axya Medical, Inc. Apparatus and method for securing suture to bone
JP2004525930A (ja) 2001-03-23 2004-08-26 バイオファーム・ゲゼルシャフト・ツア・バイオテクノロジシェン・エントヴィックルング・フォン・ファーマカ・ミット・ベシュレンクテル・ハフツング 皮膚関連疾患の治療及び診断のためのＴＧＦ−βスーパーファミリーのサイトカインの使用
US7148051B2 (en) 2004-08-16 2006-12-12 E. I. Du Pont De Nemours And Company Production of 3-hydroxycarboxylic acid using nitrilase

Also Published As

Publication number Publication date
AU2006314713B2 (en) 2011-10-06
EP1948689A1 (en) 2008-07-30
CA2627370C (en) 2016-02-23
AU2006314713A1 (en) 2007-05-24
PT1948689E (pt) 2012-05-09
US20150057223A1 (en) 2015-02-26
US9200048B2 (en) 2015-12-01
US8188226B2 (en) 2012-05-29
ATE553123T1 (de) 2012-04-15
US20080318860A1 (en) 2008-12-25
JP5654730B2 (ja) 2015-01-14
PL1948689T3 (pl) 2012-09-28
CA2627370A1 (en) 2007-05-24
CY1112877T1 (el) 2016-04-13
WO2007057212A1 (en) 2007-05-24
ES2382464T3 (es) 2012-06-08
SI1948689T1 (sl) 2012-09-28
EP1948689B1 (en) 2012-04-11
US20120322729A1 (en) 2012-12-20
JP2009519008A (ja) 2009-05-14

Similar Documents

Publication Publication Date Title
CY1112877T1 (el) Μεταλλαγματα αυξητικου παραγoντα υψηλης δραστικοτητας
WO2006092213A8 (de) Pyrazolylcarboxanilide
AU2010246102A8 (en) Pesticidal compositions
MX343042B (es) Compuestos heteroarilicos biciclicos.
UA87153C2 (ru) Энантиомерно чистые аминогетероарильные соединения как ингибиторы протеинкиназы
TW200722079A (en) Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
GB2437009A (en) Ranking system
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
NO20082298L (no) Kaliumkanalinhibitorer
CO6241120A2 (es) (DIHIDRO)PIRROLO[2,1-á]ISOQUINOLINAS.
EA200801560A1 (ru) Бифенилкарбоксамиды
UA93531C2 (en) Novel hydrogen sulfate salt
EA200702529A1 (ru) Фунгицидная комбинация биологически активных веществ
EA200701707A1 (ru) Пиразолопиримидины
ATE483000T1 (de) Naphtalin-amidin-imide
FR2917944B1 (fr) Pretailleuse de cultures palissees, en particulier de la vigne.
DK1809123T3 (da) Dimensionsstabilt foder til selskabsdyr med lavt indhold af carbohydrat
EA200801414A1 (ru) Кальцилитические соединения
EP1842910A4 (en) PROCESS FOR ENZYMATIC SYNTHESIS OF A 3'-PHOSPHOADENOSINE-5'-PHOSPHOSULFATE
TW200738713A (en) Diazepinoquinolines, synthesis thereof, and intermediates thereto
DK1856249T3 (da) Vækstfaktormutanter med forbedret biologisk aktivitet
ITRM20050556A1 (it) Struttura di ancoraggio per organismi vegetali.
DE602004030231D1 (de) Pyrimidinonverbindungen als calcilytica
RU2008136668A (ru) Пептиды, обладающие нейротропной активностью